Literature DB >> 23944684

High-caloric food supplements in the treatment of amyotrophic lateral sclerosis: a prospective interventional study.

Johannes Dorst1, Joschka Cypionka, Albert C Ludolph.   

Abstract

Weight loss is an independent prognostic factor in amyotrophic lateral sclerosis (ALS). We investigated whether the body weight of ALS patients who previously lost weight can be stabilized by a high-caloric diet. For this purpose we compared two different high-caloric food supplements: one with high fat content and one with high carbohydrate content. Twenty-six patients were randomly allocated to one of the therapeutic groups. Body weight, ALS functional rating scale-revised (ALSFRS-R), static vital capacity (SVC), bioelectrical impedance analysis (BIA), metabolic serum parameters, and adverse events were investigated. Results showed that body weight of ALS patients could be stabilized in both therapeutic groups after 12 weeks of therapy (p = 0.008). The effect was greater in the group with high fat supplement though not statistically significant (p = 0.37). In conclusion, high-caloric food supplements with high fat as well as high carbohydrate content are both suitable to stabilize the body weight of ALS patients. The effect of a high fat diet might be more pronounced. Since body weight is an independent prognostic factor in ALS it is possible that a high-caloric food supplement improves survival in ALS. However, this hypothesis can only be tested by conducting a placebo-controlled double-blinded trial of sufficient power.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23944684     DOI: 10.3109/21678421.2013.823999

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  30 in total

Review 1.  Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis.

Authors:  Richard S Bedlack; Nanette Joyce; Gregory T Carter; Sabrina Paganoni; Chafic Karam
Journal:  Neurol Clin       Date:  2015-09-08       Impact factor: 3.806

Review 2.  [Amyotrophic lateral sclerosis. Multisystem degeneration].

Authors:  A Hübers; A C Ludolph; A Rosenbohm; E H Pinkhardt; J H Weishaupt; J Dorst
Journal:  Nervenarzt       Date:  2016-02       Impact factor: 1.214

Review 3.  Symptom Management and End-of-Life Care in Amyotrophic Lateral Sclerosis.

Authors:  Carlayne E Jackson; April L McVey; Stacy Rudnicki; Mazen M Dimachkie; Richard J Barohn
Journal:  Neurol Clin       Date:  2015-11       Impact factor: 3.806

4.  Canadian best practice recommendations for the management of amyotrophic lateral sclerosis.

Authors:  Christen Shoesmith; Agessandro Abrahao; Tim Benstead; Marvin Chum; Nicolas Dupre; Aaron Izenberg; Wendy Johnston; Sanjay Kalra; Desmond Leddin; Colleen O'Connell; Kerri Schellenberg; Anu Tandon; Lorne Zinman
Journal:  CMAJ       Date:  2020-11-16       Impact factor: 8.262

5. 

Authors:  Christen Shoesmith; Agessandro Abrahao; Tim Benstead; Marvin Chum; Nicolas Dupre; Aaron Izenberg; Wendy Johnston; Sanjay Kalra; Desmond Leddin; Colleen O'Connell; Kerri Schellenberg; Anu Tandon; Lorne Zinman
Journal:  CMAJ       Date:  2020-11-16       Impact factor: 8.262

6.  Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial.

Authors:  Anne-Marie Wills; Jane Hubbard; Eric A Macklin; Jonathan Glass; Rup Tandan; Ericka P Simpson; Benjamin Brooks; Deborah Gelinas; Hiroshi Mitsumoto; Tahseen Mozaffar; Gregory P Hanes; Shafeeq S Ladha; Terry Heiman-Patterson; Jonathan Katz; Jau-Shin Lou; Katy Mahoney; Daniela Grasso; Robert Lawson; Hong Yu; Merit Cudkowicz
Journal:  Lancet       Date:  2014-02-28       Impact factor: 79.321

7.  Cognition and eating behavior in amyotrophic lateral sclerosis: effect on survival.

Authors:  R M Ahmed; J Caga; E Devenney; S Hsieh; L Bartley; E Highton-Williamson; E Ramsey; M Zoing; G M Halliday; O Piguet; J R Hodges; M C Kiernan
Journal:  J Neurol       Date:  2016-06-03       Impact factor: 4.849

8.  Life course body mass index and risk and prognosis of amyotrophic lateral sclerosis: results from the ALS registry Swabia.

Authors:  Raphael Simon Peter; Angela Rosenbohm; Luc Dupuis; Torben Brehme; Jan Kassubek; Dietrich Rothenbacher; Gabriele Nagel; Albert Christian Ludolph
Journal:  Eur J Epidemiol       Date:  2017-10-03       Impact factor: 8.082

9.  Additive Neuroprotective Effects of the Multifunctional Iron Chelator M30 with Enriched Diet in a Mouse Model of Amyotrophic Lateral Sclerosis.

Authors:  Sagit Golko-Perez; Silvia Mandel; Tamar Amit; Lana Kupershmidt; Moussa B H Youdim; Orly Weinreb
Journal:  Neurotox Res       Date:  2015-11-18       Impact factor: 3.911

10.  Body composition in amyotrophic lateral sclerosis subjects and its effect on disease progression and survival.

Authors:  Rup Tandan; Evan A Levy; Diantha B Howard; John Hiser; Nathan Kokinda; Swatee Dey; Edward J Kasarskis
Journal:  Am J Clin Nutr       Date:  2022-05-01       Impact factor: 8.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.